AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes, +35

Cancer Discovery

Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

Pedro J. Beltran, Patricia L. Mitchell, Gordon Moody, +5

Journal of Clinical Oncology

Human GrowthImmunologyPathologyInsulin ReceptorCancer Biology +18

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Susannah L. Hewitt, D. R. Shackleton Bailey, John Zielinski, +29

Clinical Cancer Research

Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

Blaire L. Osborn, Henrik S. Olsen, Bernardetta Nardelli, +6

Journal of Pharmacology and Experimental Therapeutics

Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT

Sandra L. Ross, Lynn Tran, Aaron Winters, +14

Cell Metabolism

Bioorganic ChemistryBiochemistryNatural SciencesMolecular MechanismMolecular Biology +4

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

Sandra L. Ross, Marika Sherman, Patricia McElroy, +5

PLoS ONE

ImmunologyImmunoeditingImmunodominanceImmunologic MechanismAntigen Processing +18

Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing’s and Osteogenic Sarcoma Models

Pedro J. Beltran, Young-Ah Chung, Gordon Moody, +6

Journal of Pharmacology and Experimental Therapeutics

An IFN- <i>β</i> -Albumin Fusion Protein That Displays Improved Pharmacokinetic and Pharmacodynamic Properties in Nonhuman Primates

Cynthia Sung, Bernardetta Nardelli, David W. LaFleur, +11

Journal of Interferon & Cytokine Research

Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Pedro J. Beltran, Frank J. Calzone, Petia Mitchell, +11

Clinical Cancer Research

Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer

Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, +26

Journal of Clinical Investigation